While NSCLC is characterised by activating mutations in oncogenes, mesothelioma on the other hand is characterised by the frequent inactivating alteration of the CDKN2A, NF2 and BAP1 tumour-suppressor genes. This evidence concerns the gene CDKN2A and mesothelioma.